Drug Trial Radar · NCT03462719
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
211
Actual
Start
Apr 17, 2018
Primary completion
Feb 26, 2021
Study completion Apr 5, 2029
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Pharmacyclics LLC.
- First posted
- Mar 12, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).
Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
IbrutinibDrug
Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.
VenetoclaxDrug
Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.
ChlorambucilDrug
Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.
ObinutuzumabDrug
Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.
Ibrutinib (as Subsequent Therapy)Drug
Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to 2 years 10 months
Locations
88 sites in 14 countries. Site status is shown where the registry gives one.
Norton Cancer Institute
Louisville, Kentucky
John Theurer Cancer Center
Hackensack, New Jersey
Novant Health
Charlotte, North Carolina
Institut - Jules Bordet
Anderlecht, Belgium
ZNA Stuivenberg
Antwerp, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Virga Jessa Ziekenhuis
Hasselt, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
Juravinski Cancer Centre
Hamilton, Ontario, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
Montreal, Quebec, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika
Brno, Czechia
Fakultni nemocnice Hradec Kralove
Hradec Králové, Czechia
Fakultni Nemocnice Ostrava
Ostrava, Czechia
Fakultni nemocnice Plzen, Hemato-onkologicke oddeleni
Pilsen, Czechia
Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie
Prague, Czechia
Aalborg University Hospital
Aalborg, Denmark
Aarhus Universitetshospital
Aarhus, Denmark
Rigshospitalet 1
Copenhagen, Denmark
Rigshospitalet
Copenhagen, Denmark
Odense Universitetshospital
Odense C, Denmark
Roskilde Sygehus
Roskilde, Denmark
CHU de Clermont Ferrand
Clermont-Ferrand, France
Hopital Claude Huriez
Lille, France
CHU Montpellier
Montpellier, France
Hopital Haut Leveque Service Maladie Du Sang
Pessac, France
Centre Hospitalier Universitaire de Reims, Hôpital Robert Debré
Reims, France
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, France
CHU Bretonneau
Tours, France
CHU-Nancy
Vandœuvre-lès-Nancy, France
Institut Gustave Roussy
Villejuif, France
Bnai Zion Medical Center
Haifa, Israel
Carmel Medical Center
Haifa, Israel
Hadassah Medical Center
Jerusalem, Israel
Western Galilee Medical Center
Nahariya, Israel
Sheba Medical Center
Ramat Gan, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.